Ethnic differences in adverse drug reactions to asthma medications: a systematic review

References

• McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting beta(2)-adrenergic receptor agonists. Pediatrics 2011;128:e1147–e1154
   PubMed Web of Science ®Google Scholar
• Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, Huiart L, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 2001;56:944–948
   PubMed Web of Science ®Google Scholar
• Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, Kohno S. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol 2003;90:646–651
   PubMed Web of Science ®Google Scholar
• Kelly HW, Natta ML, Van Covar RA, Tonascia J, Green RP, Strunk RC. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood asthma management program (CAMP) study. Pediatrics 2008;122:e53–e61
   PubMed Web of Science ®Google Scholar
• Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, Shingo S, Reiss TF. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001;31:77–87
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788–797
   PubMed Web of Science ®Google Scholar
• Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. US FDA, Center for Drug Evaluation and Research 2008
   Google Scholar
• Wooltorton E. Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ 2004;170:1668
   PubMed Web of Science ®Google Scholar
• Guilpain P, Pagnoux C, Lhote F, Mouthon L, Guillevin L. Antileukotrienes and Churg–Strauss syndrome. Press Med 2007;36:890–894
   PubMed Web of Science ®Google Scholar
• Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, Schwartz L. American academy of allergy, asthma & immunology/American college of allergy, asthma & immunology omalizumab-associated anaphylaxis joint task force follow-up report. J Allergy Clin Immunol 2011;128:210–212
   PubMed Web of Science ®Google Scholar
• Frampton GK, Shepherd J, Dorne J-L. Demographic data in asthma clinical trials: a systematic review with implications for generalizing trial findings and tackling health disparities. Soc Sci Med 2009;69:1147–1154
   PubMed Web of Science ®Google Scholar
• Xie H-G, Stein CM, Kim RB, Xiao ZS, He N, Zhou HH, Gainer JV, et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenet Genomics 1999;9:511–516
   Google Scholar
• Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505–1512
   PubMed Web of Science ®Google Scholar
• Hall IP, Sayers I. Pharmacogenetics and asthma: false hope or new dawn? Eur Respir J 2007;29:1239–1245
   PubMed Web of Science ®Google Scholar
• Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, Torres A, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005;171:563–570
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest J 2006;129:15–26
   PubMed Web of Science ®Google Scholar
• Dorne J. Human variability in hepatic and renal elimination: implications for risk assessment. J Appl Toxicol 2007;27:411–420
   PubMed Web of Science ®Google Scholar
• Nave R, Fisher R, McCracken N. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respir Res 2007;8:65–73
   PubMed Web of Science ®Google Scholar
• Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, et al. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: a prospective, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2008;30:1492–1504
   PubMed Web of Science ®Google Scholar
• Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006;28:73–85
   PubMed Web of Science ®Google Scholar
• Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma. J Allergy Clin Immunol 1998;102:789–796
   PubMed Web of Science ®Google Scholar
• Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:e48
   PubMed Web of Science ®Google Scholar
• Garcia MLG, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6-to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005;116:360–369
   PubMed Web of Science ®Google Scholar
• Adelsberg J, van Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6-to 24-month-old patients with asthma. Curr Med Res Opin 2005;21:971–979
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–190
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–316
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:e36
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210–1216
   PubMed Web of Science ®Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 2012;49:288–293
   PubMed Web of Science ®Google Scholar
• Donohue JF, Hanania NA, Ciubotaru RL, Noe L, Pasta DJ, Schaefer K, Claus R, et al. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther 2008;30:989–1002
   PubMed Web of Science ®Google Scholar
• Bukstein DA, Bratton DL, Firriolo KM, Estojak J, Bird SR, Hustad CM, Edelman JM. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 2003;40:475–485
   PubMed Web of Science ®Google Scholar
• Quadrel M, Lavery RF, Jaker M, Atkin S, Tortella BJ, Cody RP. Prospective, randomized trial of epinephrine, metaproterenol, and both in the prehospital treatment of asthma in the adult patient. Ann Emerg Med 1995;26:469–473
   PubMed Web of Science ®Google Scholar
• Ramsdell JW, Klinger NM, Ekholm BP, Colice GL. Safety of long-term treatment with HFA albuterol. Chest J 1999;115:945–951
   PubMed Web of Science ®Google Scholar
• Nelson H, Bonuccelli C, Radner F, Ottosson A, Carroll KJ, Andersson TL, LaForce C. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010;125:390–396. e8
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Nathan RA, Howland WC, Minkwitz MC, Simonson SG, Bonuccelli CM. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. J Allergy Clin Immunol 1999;103:246–254
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Lampl KL, Dowling Jr PJ, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000;22:732–747
   PubMed Web of Science ®Google Scholar
• Schatz M, Dombrowski MP, Wise R, Momirova V, Landon M, Mabie W, Newman RB, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 2004;113:1040–1045
   PubMed Web of Science ®Google Scholar
• Long AA, Fish JE, Rahmaoui A, Miller MK, Bradley MS, Taki HN, Demeo AN, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009;103:212–219
   PubMed Web of Science ®Google Scholar
• Bracken MB, Triche EW, Belanger K, Saftlas A, Beckett WS, Leaderer BP. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol 2003;102:739–752
   PubMed Web of Science ®Google Scholar
• Namazy J, Schatz M, Long L, Lipkowitz M, Lillie MA, Voss M, Deitz RJ, Petitti D. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004;113:427–432
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention - 2012. Available from: www.ginasthma.org [last accessed 15 May 2013
   Google Scholar